

SELECTED FINANCIAL DATA

The following table sets forth selected financial information with respect to Edwards Lifesciences. The information set forth below should be read in conjunction with Edwards Lifesciences' "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Consolidated Financial Statements" found elsewhere in this document. No per share data for the years 2000 and

prior have been presented because Edwards Lifesciences' earnings were part of Baxter's earnings through the close of business on March 31, 2000. See Note 4 to the "Consolidated Financial Statements" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" for discussions of the effect of certain asset divestitures on Edwards Lifesciences' operations.

As of or for the years ended December 31 (in millions, except per share data)	2002	2001	2000	1999	1998
Operating Results^(a)					
Net sales	\$ 704.0	\$ 692.1	\$ 803.8	\$ 905.0	\$ 865.0
Gross profit	404.9	368.4	380.5	439.0	399.0
Income (loss) from continuing operations ^(b)	55.7	(11.4)	(271.7)	82.0	62.0
Balance Sheet Data					
Total assets ^(c)	\$ 1,008.2	\$ 982.9	\$ 1,106.7	\$ 1,437.0	\$ 1,483.0
Long-term debt and lease obligations	245.5	309.8	367.2	—	—
Common Stock Information					
Income (loss) from continuing operations per common share:					
Basic	\$ 0.94	\$ (0.19)	\$ —	\$ —	\$ —
Diluted	0.91	(0.19)	—	—	—
Cash dividends declared per common share	—	—	—	—	—

(a) The results prior to April 1, 2000 present Edwards Lifesciences on a divisional basis as it had historically been operated as part of Baxter. From April 1, 2000 (the date following the distribution of the Company's common stock to stockholders of Baxter) to September 30, 2002, Edwards Lifesciences Japan business is presented on an equity basis as opposed to the consolidation method reflected in the historical results. Commencing October 1, 2002, the Company began reporting the results of its Japan business on a fully consolidated basis. See "Joint Venture in Japan" in Management's Discussion and Analysis of Financial Condition and Results of Operations for more information.

(b) See Note 4 to the "Consolidated Financial Statements" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" for additional information regarding non-recurring charges of \$67.4 million, \$83.0 million and \$312.2 million during 2002, 2001 and 2000, respectively.

(c) See Note 4 to the "Consolidated Financial Statements" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" for additional information regarding the write down of goodwill of \$80.7 million and \$282.0 million during 2001 and 2000, respectively.